ERBB2 and breast carcinoma: In the current multicenter, single‐arm study, our aim was to investigate the efficacy and safety of epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab, and pyrotinib (ECPy‐THPy) for the neoadjuvant treatment of patients with HER2‐positive breast cancer.